More Than a Decade Since the Latest CONSORT Non-inferiority Trials Extension: Do Infectious Diseases Trials Do Enough?

Adam S Komorowski; Carson K L Lo; Andrew K Kapoor; Marek Smieja; Mark Loeb; Dominik Mertz; Anthony D Bai

doi:10.1093/cid/ciad574

More Than a Decade Since the Latest CONSORT Non-inferiority Trials Extension: Do Infectious Diseases Trials Do Enough?

Clin Infect Dis. 2024 Feb 17;78(2):324-329. doi: 10.1093/cid/ciad574.

Authors

Adam S Komorowski^{1

2}, Carson K L Lo³, Andrew K Kapoor⁴, Marek Smieja^{1

2

4}, Mark Loeb^{1

2

4}, Dominik Mertz^{2

4}, Anthony D Bai⁵

Affiliations

¹ Medical Microbiology, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
² Department of Health Research Methodology, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
³ Transplant Infectious Diseases and Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
⁵ Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Ontario, Canada.

PMID: 37739456
DOI: 10.1093/cid/ciad574

Abstract

More than a decade after the Consolidated Standards of Reporting Trials group released a reporting items checklist for non-inferiority randomized controlled trials, the infectious diseases literature continues to underreport these items. Trialists, journals, and peer reviewers should redouble their efforts to ensure infectious diseases studies meet these minimum reporting standards.

Keywords: anti-infective agents; data quality; non-inferiority trials; randomized controlled trials as topic; research design.

MeSH terms

Checklist*
Humans
Reference Standards
Research Design*